Table 1.
Classifications of Medicines for Malaria Venture TCP and TPPs
| Target Candidate Profiles | ||
|---|---|---|
| Profile | Plasmodium lifecycle stage target | Notes |
| TCP1 | Asexual blood stages | Active against resistant strains of Plasmodium |
| Symptomatic treatment | ||
| TCP3 | Dormant liver-stage hypnozoites | Improved safety compared to primaquine and tafenoquine |
| Anti-relapse | ||
| TCP4 | Hepatic schizonts | Effective at equal/lower dose to TCP1 treatment |
| Chemoprotection | ||
| TCP5 | Gametocytes/Gametes | Low dose, less than TCP1 treatment |
| Transmission blocking | ||
| TCP6 | Insect vector (endectocides) | Low dose, less than TCP1 treatment |
| Transmission blocking | ||
| Target Product Profiles | ||
|---|---|---|
| Profile | TCPs Addressed | Notes |
| TPP1 | TCP1 | Single or multiple treatment medicines for treatment of: Severe malaria (TCP1) |
| TCP3 | Uncomplicated malaria and preventative treatment (TCP1) | |
| Case Management | TCP5 | Relapsing malaria (TCP3) |
| TCP6 | Asymptomatic stages for population protection (TCP5 & 6) | |
| TPP2 | TCP1 | In the case of epidemics or for migratory populations |
| Chemoprotection | TCP4 | |